The impact of HPV/HIV co-infection on immunosuppression, HPV genotype, and cervical cancer biomarkers

Abstract Background Human papillomavirus (HPV) and human immunodeficiency virus (HIV) co-infection present a significant impact on women's health globally, especially in immunocompromised individuals. HIV-induced immunosuppression promotes the persistence of high-risk HPV infection and increase...

Full description

Saved in:
Bibliographic Details
Main Authors: Terkimbi Dominic Swase, Ilemobayo Victor Fasogbon, Ifie Josiah Eseoghene, Ekom Monday Etukudo, Solomon Adomi Mbina, Chebet Joan, Reuben Samson Dangana, Chinyere Anyanwu, Comfort Danchal Vandu, A. B Agbaje, Tijjani Salihu Shinkafi, Ibrahim Babangida Abubarkar, Patrick Maduabuchi Aja
Format: Article
Language:English
Published: BMC 2025-02-01
Series:BMC Cancer
Subjects:
Online Access:https://doi.org/10.1186/s12885-025-13516-2
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Human papillomavirus (HPV) and human immunodeficiency virus (HIV) co-infection present a significant impact on women's health globally, especially in immunocompromised individuals. HIV-induced immunosuppression promotes the persistence of high-risk HPV infection and increased the progression to cervical cancer. The aim of this systematic review was to assessed the impact of HPV/HIV co-infection on the prevalence and distribution of HR-HPV genotypes, the level of immunosuppression and expression of cervical cancer biomarkers. Method The article selection method for this review was based on the 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards. The total of eighty-four (84) articles from standard electronic databases mainly Web of Science, PubMed, and Scopus were extracted and reviewed. The articles were published in English between 2008 and 2024 and comprised a total of 80023 participants. Results The HR-HPV genotypes reported across various studies include HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 70, 73, and 82. Among HIV positive individuals, the most common circulating HR-HPV genotypes were HPV16, 18, 45, 35, and 58, accounted for 11%, 10%, 9%, 8%, and 8% of cases, respectively. Approximately 29.1% and 30.0% of patients had CD4 counts of 200–400 cells/L and 300–400 cells/L, respectively. The most commonly reported cervical cancer biomarkers were p16INK4a and Ki-67, according to the analysis. Conclusion The findings indicate high prevalence of multiple HR-HPV genotypes among HIV positive individuals, indicating the impact of HPV/HIV co-infection on immunosuppression and persistence of HPV infection. The expression of cervical cancer biomarker such as p16INK4a and Ki-67 emphasized target screening and early detection strategy in high-risk population. However, there was no direct impact of HPV/HIV co-infection reported on these biomarkers and required to be studied more especially in people living with HIV.
ISSN:1471-2407